[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "SEQUENTIAL_ASSIGNMENT",
        "lead_org": "Compass Therapeutics",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Age 18 years or older"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Histologically confirmed diagnosis of metastatic or locally advanced malignancies"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Measurable disease per RECIST 1.1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Disease progression after at least 12 weeks and at least 2 doses of a commercially available PD-1 or PD-L1 inhibitor per approved prescriber's information, whether monotherapy or in combination therapy, with no other intervening systemic anticancer therapy prior to enrollment"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Eastern Cooperative Oncology Group (ECOG) performance status 0-1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Life expectancy > 12 weeks"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Adequate bone marrow function defined by ANC of \u2265 1.5\u00d710^9/L, platelet count of \u2265100.0\u00d710^9/L, and hemoglobin of \u2265 9.0 g/dL (with or without transfusion)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "Adequate hepatic function defined as serum total bilirubin < 2 mg/dL, AST/ALT \u2264 2.5 \u00d7 ULN (or \u2264 5 \u00d7 ULN in patients with liver metastases)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Adequate renal function defined as serum creatinine < 1.5 \u00d7 ULN or with normal serum creatinine levels defined as creatinine clearance > 60 mL/min as determined by the Cockcroft-Gault equation"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "Female patients who are women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-471"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "Last dose of previous PD-1 or PD-L1 therapy \u2265 28 days, other anticancer therapy > 21 days (or 2 half-lives for proteins, whichever is longer), radiotherapy > 21 days (concurrent localized palliative radiotherapy is allowed during CTX-471 treatment), or surgical intervention >21 days prior to the first dose of CTX-471"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 12,
                    "description": "Resolution of all prior anti-cancer therapy toxicities \u2264 Grade 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 13,
                    "description": "Willingness to provide pre- and post-treatment fresh tumor biopsies"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 14,
                    "description": "Capable of understanding and complying with protocol requirements"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 15,
                    "description": "Signed and dated institutional review board/independent ethics committee-approved informed consent form before any protocol-directed screening procedures are performed"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 16,
                    "description": "Developed clinically significant adverse reaction to PD-1 or PD-L1 therapy, including immune related adverse reactions, which led to discontinuation of treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 17,
                    "description": "Prior treatment with other investigational immune-oncology therapies"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 18,
                    "description": "Systemic therapy with immunosuppressive agents within 7 days before the start of CTX-471 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 19,
                    "description": "Patient is a pregnant or lactating WCBP"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 20,
                    "description": "Prior organ transplantation"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 21,
                    "description": "Active hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection or a positive serological test at Screening within 28 days of dosing with CTX 471"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 22,
                    "description": "Active autoimmune disease or medical conditions requiring chronic steroid (ie, > 10 mg/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 23,
                    "description": "History of central nervous system metastases"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 24,
                    "description": "History of seizure disorders"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 25,
                    "description": "Congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 26,
                    "description": "Other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": null,
        "official_title": "A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies",
        "_phase_sort_order": 4,
        "collaborators": [
            {
                "name": "Iqvia Pty Ltd",
                "functional_role": "LABORATORY"
            }
        ],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)",
                "name": "Area under the serum concentrations of CTX-471 versus time curve (AUC)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)",
                "name": "Development of anti-drug antibodies (ADAs) and/or neutralizing antibodies of CTX-471",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)",
                "name": "Dose(s) of CTX 471 to be examined in Part 2 and the recommended Phase 2 dose(s)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "From the date of first confirmed CR or PR until the first date of recurrent or progressive disease (up to 2 years)",
                "name": "Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)",
                "name": "Half-life (t1/2) of serum concentrations of CTX-471",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)",
                "name": "Maximum serum concentration (Cmax) of CTX-471",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)",
                "name": "Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline until confirmed disease progression (CR or PR) (up to 2 years)",
                "name": "Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",
                "description": "ORR will be calculated as the number of participants with a confirmed complete response (CR) or a partial response (PR) divided by the number of participants dosed",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until death (up to 2 years)",
                "name": "Overall Survival (OS)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From first dose of CTX-471 (Week 1 Day 1) until disease progression or death, whichever occur first (up to 2 years)",
                "name": "Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",
                "description": null,
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 2,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT03881488",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2019-05-17",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Solid Tumor",
                    "Metastatic Tumor",
                    "Metastatic Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Locally Advanced Solid Tumor",
                    "Locally Advanced Malignant Solid Neoplasm",
                    "Locally Advanced Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C133093",
                "name": "Locally Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C8524",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Malignant Hematopoietic Neoplasm",
                    "Hematopoietic Neoplasms Including Lymphomas",
                    "HEMOLYMPHORETICULAR TUMOR, MALIGNANT",
                    "Hematopoietic Cancer",
                    "Hematopoietic and Lymphoid Neoplasm",
                    "Hematologic Cancer",
                    "Hematologic Malignancy",
                    "Hematologic Neoplasm",
                    "Malignant Hematologic Neoplasm",
                    "Hematological Neoplasm",
                    "Hematopoietic malignancy, NOS",
                    "Hematopoietic Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C27134",
                "name": "Hematopoietic and Lymphoid Cell Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C26323",
                    "C35813",
                    "C4741"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Malignancy",
                    "Secondary Cancer"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C36255"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, secondary",
                    "Secondary Tumor",
                    "Tumor, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Tumor",
                    "Tumor, metastatic",
                    "Neoplasm, metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasms, NOS",
                    "Neoplasia",
                    "Tumor, NOS",
                    "Neoplastic Growth",
                    "Neoplasm",
                    "Neoplastic Disease",
                    "tumor",
                    "Neoplasm, NOS"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Disease",
                    "Diseases and Disorders",
                    "disease type",
                    "Disease or Disorder",
                    "Diagnosis",
                    "disease_term",
                    "condition",
                    "disease_type",
                    "Diseases",
                    "Disease or Disorder, Non-Neoplastic",
                    "Disorders",
                    "Disorder"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Malignant Growth",
                    "Tumor, malignant, NOS",
                    "Malignant Tumor",
                    "Malignancy",
                    "CA",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Tumour",
                    "Solid tumor, NOS",
                    "Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Locally Advanced Cancer",
                    "Locally advanced",
                    "regional cancer",
                    "Locally Metastatic Malignant Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C8524",
                "name": "Locally Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Disease by Site"
                ],
                "nci_thesaurus_concept_id": "C27551",
                "name": "Disorder by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C3263",
                "name": "Neoplasm by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Tumor Morphology",
                    "Tumor_Morphology"
                ],
                "nci_thesaurus_concept_id": "C4741",
                "name": "Neoplasm by Morphology",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Hematopoietic and Lymphoid System Disease"
                ],
                "nci_thesaurus_concept_id": "C35814",
                "name": "Hematopoietic and Lymphoid System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27551"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Hematopoietic and Lymphoid System Tumor"
                ],
                "nci_thesaurus_concept_id": "C35813",
                "name": "Hematopoietic and Lymphoid System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3263",
                    "C35814"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Blood Disease",
                    "Blood Disorder",
                    "Hematological Disorder",
                    "Hematologic Disorder"
                ],
                "nci_thesaurus_concept_id": "C26323",
                "name": "Hematologic and Lymphocytic Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C35814"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "CTX-471-001",
        "active_sites_count": 4,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunopotentiators",
                            "Biological Response Modifier",
                            "BRM",
                            "Immune Regulators",
                            "Immune Modulators",
                            "Immune Mediators",
                            "Biomodulators",
                            "Immunomodulating Agent",
                            "Immunomodulators",
                            "Immunotherapeutic Agent",
                            "Immunomodulatory Agent",
                            "Immunotherapy Agent"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-4-1BB Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C155745",
                        "name": "Anti-CD137 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Monoclonal Antibodies",
                            "Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C20401",
                        "name": "Monoclonal Antibody Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C307",
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceuticals",
                            "Agent",
                            "Pharmacological Substance",
                            "Drug Substance",
                            "Pharmaceutical Agent",
                            "Drug",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunologic, Immunochemical",
                            "Immunologics",
                            "Biopharmaceuticals",
                            "Biologicals",
                            "Biologics",
                            "Biological Products"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C162039",
                        "name": "Anti-CD137 Agonistic Monoclonal Antibody CTX-471",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C155745"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Part 1 Dose Escalation",
                "description": "Escalating doses of CTX-471 depending on cohort at enrollment.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 2 Dose Expansion",
                "description": "Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2019-04007",
        "why_study_stopped": null,
        "brief_summary": "This is a Phase 1, open-label, first-in-human study of CTX-471 monotherapy in patients with\r\n      metastatic or locally advanced malignancies that have progressed while receiving an approved\r\n      PD-1 or PD-L1 inhibitor. The study will be conducted in 2 parts: Part 1 Dose Escalation and\r\n      Part 2 Dose Expansion.",
        "brief_title": "Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies",
        "status_history": [
            {
                "status_date": "2019-05-17T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 96,
        "_current_trial_status_sort_order": 0,
        "start_date": "2019-05-17",
        "record_verification_date": "2021-09-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": null,
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2022-09-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]